



ASX ANNOUNCEMENT

10 March 2009

Further Investment in Tissue Therapies Ltd

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** has announced today that due to a number of practical difficulties outside their control, two sophisticated investors were unable to return completed application forms prior to the close of the recently announced Rights Issue (**ASX: TIS Rights Issue Exceeds Expectations, 4 March 2009**).

Having considered all of the circumstances, the Tissue Therapies Board has resolved to issue shortfall shares to these two shareholders to a total of 910,000 shares at \$0.12 each, increasing the proceeds of the Rights Issue by a further \$109,200

This share issue is made under the provisions of Clause 1.7 of the Rights Issue Prospectus released on 28 January 2009 (**ASX: TIS 1:2 Non-Renounceable Rights Issue Prospectus**).

As a result of the issue of these shares, the total number of new shares issued from the Rights Issue is 15.6 million with total funds raised of \$1.87 million.

Updated Appendix 3B, List of Top 20 Investors and Notice 708 follow.

Further information:

Dr Steven Mercer
CEO, Tissue Therapies Limited
Telephone: +61 (0)7 3839 9938

Email: s.mercer@tissuetherapies.com

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective medical treatments for wound healing including chronic ulcers and burns,

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Name of entity

Tissue Therapies Limited

ABN

ABN 45 101 955 088

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- | | | |
|---|--|--|
| 1 | +Class of +securities issued or to be issued | Ordinary shares. |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued | 910,000 additional ordinary shares issued under the Company's 2009 Rights Issue Prospectus. |
| 3 | Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | Fully paid ordinary shares issued at \$0.12 per share and ranking equally with all other fully paid ordinary shares. |

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

<p>4 Do the ⁺securities rank equally in all respects from the date of allotment with an existing ⁺class of quoted ⁺securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none"> • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	<p>Ordinary shares rank equally in all respects.</p>				
<p>5 Issue price or consideration</p>	<p>\$0.12 per ordinary share.</p>				
<p>6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<p>Further working capital to support the company's ongoing research and clinical trial program and for the GMP manufacturing of VitroGro®.</p>				
<p>7 Dates of entering ⁺securities into uncertificated holdings or despatch of certificates</p>	<p>9 March 2009.</p>				
<p>8 Number and ⁺class of all ⁺securities quoted on ASX (including the securities in clause 2 if applicable)</p>	<table border="1"> <thead> <tr> <th data-bbox="686 1400 989 1444">Number</th> <th data-bbox="989 1400 1281 1444">⁺Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="686 1444 989 1664">72,306,145</td> <td data-bbox="989 1444 1281 1664">Ordinary fully paid shares.</td> </tr> </tbody> </table>	Number	⁺ Class	72,306,145	Ordinary fully paid shares.
Number	⁺ Class				
72,306,145	Ordinary fully paid shares.				

+ See chapter 19 for defined terms.

	Number	+Class
9 Number and +class of all +securities not quoted on ASX (including the securities in clause 2 if applicable)	1,345,000 options (total) constituted by:	
	100,000 options	Exercisable at 95c each before 27 September 2009.
	40,000 options	Exercisable at not less than 80c each on the achievement by the CEO of specified milestones for a period of 2 years from the date of the achievement of each milestone.
	205,000 options	Exercisable at 64c each before 29 August 2009.
	400,000 options	Exercisable at 64c each on the achievement by the CEO of specified milestones for a period of 2 years from the date of the achievement of each milestone.
	100,000 options	Exercisable at 64c each before 29 November 2009.
	500,000 options	Exercisable at 15c each on the achievement by the CEO of specified milestones for a period of 2 years from the date of the achievement of each milestone.

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	Same as policy on all existing quoted ordinary shares.
---	--

Part 2 - Bonus issue or pro rata issue

11 Is security holder approval required?	No.
--	-----

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

- | | | |
|----|---|---|
| 12 | Is the issue renounceable or non-renounceable? | Non-renounceable. |
| 13 | Ratio in which the +securities will be offered | 1:2 – 1 new share will be issued for every 2 existing shares held. |
| 14 | +Class of +securities to which the offer relates | Ordinary shares. |
| 15 | +Record date to determine entitlements | 10 February 2009. |
| 16 | Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? | No. |
| 17 | Policy for deciding entitlements in relation to fractions | Fractional entitlements will be rounded up to the nearest whole share. |
| 18 | Names of countries in which the entity has +security holders who will not be sent new issue documents

Note: Security holders must be told how their entitlements are to be dealt with.

Cross reference: rule 7.7. | Only eligible Shareholders with a registered address in Australia and New Zealand will be sent issue documents. Other Shareholders will not receive an entitlement. |
| 19 | Closing date for receipt of acceptances or renunciations | 27 February 2009. |

+ See chapter 19 for defined terms.

20	Names of any underwriters	Nil.
21	Amount of any underwriting fee or commission	Nil.
22	Names of any brokers to the issue	Refer to item 20.
23	Fee or commission payable to the broker to the issue	Nil.
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders	The Company will pay a handling fee to ASX participating organisations of 1.5% on the value of all stamped Entitlement and Acceptance Forms, capped at \$300 per Acceptance.
25	If the issue is contingent on +security holders' approval, the date of the meeting	N/A.
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	13 February 2009.
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	Nil.
28	Date rights trading will begin (if applicable)	N/A (non-renounceable).
29	Date rights trading will end (if applicable)	N/A (non-renounceable).
30	How do +security holders sell their entitlements <i>in full</i> through a broker?	N/A (non-renounceable).
31	How do +security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A (non-renounceable).

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

- 32 How do ⁺security holders dispose of their entitlements (except by sale through a broker)? N/A (non-renounceable)
- 33 ⁺Despatch date 9 March 2009.

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of securities
(tick one)
- (a) Securities described in Part 1
- (b) All other securities
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

- 35 If the ⁺securities are ⁺equity securities, the names of the 20 largest holders of the additional ⁺securities, and the number and percentage of additional ⁺securities held by those holders
- 36 If the ⁺securities are ⁺equity securities, a distribution schedule of the additional ⁺securities setting out the number of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over
- 37 A copy of any trust deed for the additional ⁺securities

+ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38 Number of securities for which
+quotation is sought

--

39 Class of +securities for which
quotation is sought

--

40 Do the +securities rank equally in all
respects from the date of allotment
with an existing +class of quoted
+securities?

If the additional securities do not
rank equally, please state:

- the date from which they do
- the extent to which they
participate for the next dividend,
(in the case of a trust,
distribution) or interest payment
- the extent to which they do not
rank equally, other than in
relation to the next dividend,
distribution or interest payment

--

41 Reason for request for quotation
now

Example: In the case of restricted securities, end of
restriction period

(if issued upon conversion of
another security, clearly identify that
other security)

--

	Number	+Class
42 Number and +class of all +securities quoted on ASX (including the securities in clause 38)		

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

Quotation agreement

- 1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the +securities on any conditions it decides.

- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.

 - There is no reason why those +securities should not be granted +quotation.

 - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.
Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

 - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.

 - If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

- 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.



Sign here: Date: 10 March 2009
(Managing Director)

Print name: Steven Mercer
=====

1896399v1/S6

+ See chapter 19 for defined terms.

TISSUE THERAPIES LIMITED

**FIRST 20 INVESTORS REPORT
TUESDAY 10 MARCH 2009**

PARAMETERS

Issuer Code : TIS
Report Name : TOP N REPORT
Security Group :
Security Code : TIS
As At Date : CURRENT
Top n : 20
Top Type : (N)UMBER
Top n OR First n : FIRST N
Investor Groups : N
Display Investors in Group : N
Display Address : N
Display HRN : N
Current OR Available Bal : CURRENT
Foreign / Domestic : ALL
Holding Exclusions :
Business / Effective Date : BUSINESS
Cross Register Reporting : No
PDF Output : Y
CSV Output : N
Orient Capital CSV Output : N

TISSUE THERAPIES LIMITED

**FIRST 20 INVESTORS REPORT
 TUESDAY 10 MARCH 2009**

<u>Rank</u>	<u>Investor</u>	<u>Current Balance</u>	<u>% Issued Capital</u>
Security: TIS - ORDINARY FULLY PAID SHARES			
1	ASIA UNION INVESTMENTS PTY LIMITED	12,750,000	17.63%
2	MR ROGER BRIAN CLARKE + MRS BARBARA JOAN CLARKE <ROGER B CLARKE FAMILY A/C>	6,460,000	8.93%
3	QUEENSLAND UNIVERSITY OF TECHNOLOGY	2,255,000	3.12%
4	DR ZEE UPTON	1,300,276	1.80%
5	BERNE NO 132 NOMINEES PTY LTD <323723 A/C>	1,043,037	1.44%
6	DYNAMIC SUPPLIES INVESTMENTS PTY LTD	1,000,000	1.38%
7	BERNE NO 132 NOMINEES PTY LTD <323731 A/C>	806,037	1.11%
8	ORBIT CAPITAL PTY LTD	612,500	.85%
9	DR NEIL GORDON CARRINGTON + DR SUZANNE BARBARA CARRINGTON	600,000	.83%
10	WAGGY TAIL PTY LTD <WW SHARE A/C>	577,575	.80%
11	GAFFBURY PTY LTD <THE SMALLSMAN FAMILY A/C>	528,876	.73%
12	MS JOANNA GIANNOU	497,180	.69%
13	BERNE NO 132 NOMINEES PTY LTD <224266 A/C>	493,751	.68%
14	MR DAVID FREDERICK OAKLEY	421,250	.58%
15	MR WAYNE MARTIN + MRS ANTHEA MARTIN	400,000	.55%
16	PSA SUPER PTY LTD <THE VESOUL SUPER FUND A/C>	356,738	.49%
17	KELWICK PTY LTD <CLARKE SUPER FUND A/C>	325,000	.45%

TISSUE THERAPIES LIMITED
FIRST 20 INVESTORS REPORT
TUESDAY 10 MARCH 2009

<u>Rank</u>	<u>Investor</u>	<u>Current Balance</u>		<u>% Issued Capital</u>
18	MR RICHARD ANTHONY O'SULLIVAN + MRS MAUREEN JENNIFER O'SULLIVAN <R O'SULLIVAN SUPER FUND A/C>	314,524		.43%
19	SALLTIN PTY LTD <SALLTIN SUPER FUND A/C>	312,363		.43%
20	MELDA INVESTMENTS PTY LTD <JANET CAFFIN SUPER FUND A/C>	307,000		.42%
TOTAL FOR TOP 20:		31,361,107	Investors 20	43.37%
TOTAL IN THIS REPORT:		31,361,107	Investors 20	43.37%
TOTAL OTHER INVESTORS:		40,945,038	1,317	56.63%
GRAND TOTAL:		72,306,145	1,337	100.00%

end of report



ASX RELEASE

Issuer: Tissue Therapies Limited (ASX Code: TIS)

Date: 10 March 2009

s708A(5)(e) Disclosure Notice – Issue of placement shares

The Company relies upon case 1 in section 708A(5) Corporations Act 2001 (**Corporations Act**) in respect of the placement of shares to sophisticated and institutional investors. The Issuer named above notifies ASX, as required by section 708A(6) Corporations Act, as the operator of the prescribed financial market, of details of the issue of securities by placement to persons in response to offers made by the Company in accordance with section 708(5)(e) Corporations Act.

Details of the securities issued

Class of securities:	Ordinary shares
ASX Code of the securities:	TIS
Date of the issue or expected issue of the securities:	9 March 2009
Total number of securities issued or expected to be issued:	910,000

Signed for and on behalf of the Issuer:

Date: 10 March 2009

Name: Drummond McKenzie

Position held: Company Secretary

Signature:

A handwritten signature in black ink, appearing to read "D McKenzie", is written over a horizontal line.

1. The above securities will or have issued without disclosure to investors under section 708A(6) of Part 6D.2 of the Corporations Act and as permitted in compliance with section 708A.
2. This notice is given under section 708A(5)(e) and in accordance with section 708A(6) of the Corporations Act.
3. As at the date of this notice, the Issuer has complied with the provisions of Chapter 2M of the Corporations Act (as modified by an ASIC declaration dated 1 July 2004) in application to the Issuer and the Issuer has complied with section 674 of the Corporations Act.
4. There is no 'excluded information' required to be set out in this notice by virtue of sections 708A(7) and (8) of the Corporations Act.
5. The securities referred to above are ordinary shares in a class of securities that were ASX quoted securities, within the meaning of section 708A(5) of the Corporations Act, at all times in the 3 months before the day on which the relevant securities were issued.

6. The securities referred to above have been trading on ASX in circumstances where trading has not been suspended for more than a total of 5 days during the shorter of the period during which the class of securities were quoted and the period of 12 months before the day on which the relevant securities were issued.
7. No exemptions under sections 111AS or 111AT of the Corporations Act cover the Issuer or any person as director or auditor of the Issuer at any time during the shorter of the period during which the class of securities were quoted and the period of 12 months before the day on which the relevant securities were issued.
8. Save as modified by the ASIC declaration of 1 July 2004, no order under sections 340 or 341 of the Corporations Act covers the Issuer or any director or auditor of the Issuer at any time during the shorter of the period during which the class of securities were quoted and the period of 12 months before the day on which the relevant securities were issued.